

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Report – August 25, 2018**  
**Data through : August 25, 2018**  
**Table 3 – Retention<sup>1</sup> by Visit and Site<sup>2</sup>**

	<b>Overall</b>	
N Enrolled	177	177
<b>Step 1</b>		
Week 2	167/173 (96.5%)	0/0 (-%)
Week 4	154/162 (95.1%)	0/0 (-%)
<b>Step 2</b>		
Week 5 (Injection #1)	144/145 (99.3%)	0/0 (-%)
Week 6 Safety Visit	139/151 (92.1%)	0/0 (-%)
Week 9 (Injection #2)	141/151 (93.4%)	0/0 (-%)
Week 13 Safety Visit	140/150 (93.3%)	0/0 (-%)
Week 17 (Injection #3)	116/124 (93.5%)	0/0 (-%)
Week 21 Safety Visit	95/103 (92.2%)	0/0 (-%)
Week 25 (Injection #4)	58/59 (98.3%)	0/0 (-%)
Week 33 (Injection #5)	7/9 (77.8%)	0/0 (-%)
Week 41 (Injection #6)	0/0 (-%)	0/0 (-%)
Week 42 Safety Visit	0/0 (-%)	0/0 (-%)
Week 49 (Injection #7)	0/0 (-%)	0/0 (-%)
Week 57 (Injection #8)	0/0 (-%)	0/0 (-%)
Week 65 (Injection #9)	0/0 (-%)	0/0 (-%)
Week 73 (Injection #10)	0/0 (-%)	0/0 (-%)
Week 81 (Injection #11)	0/0 (-%)	0/0 (-%)
Week 89 (Injection #12)	0/0 (-%)	0/0 (-%)
Week 97 (Injection #13)	0/0 (-%)	0/0 (-%)
Week 105 (Injection #14)	0/0 (-%)	0/0 (-%)
Week 113 (Injection #15)	0/0 (-%)	0/0 (-%)
Week 121 (Injection #16)	0/0 (-%)	0/0 (-%)
Week 129 (Injection #17)	0/0 (-%)	0/0 (-%)
Week 137 (Injection #18)	0/0 (-%)	0/0 (-%)
Week 145 (Injection #19)	0/0 (-%)	0/0 (-%)
Week 153 (Injection #20)	0/0 (-%)	0/0 (-%)
Week 161 (Injection #21)	0/0 (-%)	0/0 (-%)
Week 169 (Injection #22)	0/0 (-%)	0/0 (-%)

<sup>1</sup>Percent of evaluated participants who completed each visit. Evaluated participants are those whose visit window has closed as of the cutoff date plus those that completed the visit although the window is not yet closed.

<sup>2</sup> Only sites with enrolled participants are shown. Inappropriately enrolled participants are excluded. There are currently 0 inappropriately enrolled participants.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for  
 Pre-Exposure Prophylaxis in HIV-Uninfected Women  
 Report – August 25, 2018  
 Data through : August 25, 2018  
 Table 3 – Retention<sup>1</sup> by Visit and Site<sup>2</sup>**

	<b>Overall</b>	
Week 177 (Injection #23)	0/0 (-%)	0/0 (-%)
Week 185 (Injection #24)	0/0 (-%)	0/0 (-%)

<sup>1</sup>Percent of evaluated participants who completed each visit. Evaluated participants are those whose visit window has closed as of the cutoff date plus those that completed the visit although the window is not yet closed.  
<sup>2</sup> Only sites with enrolled participants are shown. Inappropriately enrolled participants are excluded. There are currently 0 inappropriately enrolled participants.